Form 8-K - Current report:
SEC Accession No. 0001494650-25-000054
Filing Date
2025-03-20
Accepted
2025-03-20 09:14:35
Documents
17
Period of Report
2025-03-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K optn-20250319.htm   iXBRL 8-K 65335
2 EX-2.1 ex-21mergeragreement.htm EX-2.1 1404377
3 EX-99.1 ex-991votingagreementxmvm.htm EX-99.1 99462
4 EX-99.2 ex-992formofvotingagreement.htm EX-99.2 99491
8 optn-20250319_g1.jpg GRAPHIC 10067
  Complete submission text file 0001494650-25-000054.txt   2090759

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT optn-20250319.xsd EX-101.SCH 1785
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT optn-20250319_lab.xml EX-101.LAB 21689
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT optn-20250319_pre.xml EX-101.PRE 12525
19 EXTRACTED XBRL INSTANCE DOCUMENT optn-20250319_htm.xml XML 2721
Mailing Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067
Business Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067 267-364-3500
OptiNose, Inc. (Filer) CIK: 0001494650 (see all company filings)

EIN.: 421771610 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38241 | Film No.: 25754673
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)